Supplementary Information from HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2⁺ Tumors

Supplemental Figure Legend, Supplementary Figure 1 Flow cytometric analysis of HER2 expression on AU565pv and BT474 tumor cells; Supplementary Figure 2 Co-treatment with panobinostat and trastuzumab does not alter splenic NK cell activation/maturation status or frequency in AU565pv tumor-bearing SCID mice; Supplementary Figure 3 Panobinostat-mediated enrichment of interferon-gamma response and chemokine associated gene signatures; Supplementary Figure 4 SCID mice bearing AU565pv tumors were treated with PBS/DMSO (Vehicle), DMSO/trastuzumab (10 mg/kg), PBS/panobinostat (15 mg/kg) or panobinostat and trastuzumab (combination); Supplementary Figure 5 Panobinostat treatment modulates expression of both the activation receptor CD69 and Fc-receptors CD16/32 on IL-2 activated mouse and human NK cells; Supplementary Figure 6 Co-treatment of panobinostat and trastuzumab attenuates HER2 expression in BT474 and BT474-MyrAKT tumor cells; Supplementary Figure 7 Panobinostat is more effective than doxorubicin at supporting the curative activity of anti-HER2 therapy in Her2/neu transgenic mice bearing established rHER2+ H2N113 mammary tumors; Supplementary Figure 8 Rejection of Bcl-2 over-expressing AU565pv tumors in SCID mice treated with the combination therapy.